MUSTANG BIO, INC. Noncash or Part Noncash Acquisition, Fixed Assets Acquired
MUSTANG BIO, INC. (MBIO) reported Noncash or Part Noncash Acquisition, Fixed Assets Acquired of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 · last filed 2026-03-19
- MUSTANG BIO, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2025-12-31 was $0.00.
- MUSTANG BIO, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2025-09-30 was $0.00.
- MUSTANG BIO, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2024-12-31 was $0.00.
- MUSTANG BIO, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2024-09-30 was $0.00.
- MUSTANG BIO, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- MUSTANG BIO, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2024 was $2.21M.
- MUSTANG BIO, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2023 was $0.00.
| Period end | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 6 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 9 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $0.00 10-K · filed 2026-03-19 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-08 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $2.21M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $2.21M 10-Q · filed 2025-11-07 | ||
| 2024-06-30 | $2.21M 10-Q · filed 2025-08-08 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $0.00 derived: sum of 2 quarters · filed 2025-03-28 | $0.00 10-K · filed 2025-03-28 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |